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ORIGINAL RESEARCH
Urinary Ethyl Glucuronide as Measure of 
Alcohol Consumption and Risk  
of Cardiovascular Disease:  
A Population- Based Cohort Study
Inge A. T. van de Luitgaarden , MD; Ilse C. Schrieks, PhD; Lyanne M. Kieneker, PhD; Daan J. Touw, PharmD, 
PhD; Adriana J. van Ballegooijen, PhD; Sabine van Oort, MD; Diederick E. Grobbee, MD, PhD;  
Kenneth J. Mukamal, MD, MPH; Jenny E. Kootstra-Ros, PhD; Anneke C. Muller Kobold, PhD;  
Stephan J. L. Bakker, PhD; Joline W. J. Beulens, PhD
BACKGROUND: Moderate alcohol consumption has been associated with a lower risk of cardiovascular disease (CVD) and all- 
cause mortality compared with heavy drinkers and abstainers. To date, studies have relied on self- reported consumption, 
which may be prone to misclassification. Urinary ethyl glucuronide (EtG) is an alcohol metabolite and validated biomarker for 
recent alcohol consumption. We aimed to examine and compare the associations of self- reported alcohol consumption and 
EtG with CVD and all- cause mortality.
METHODS AND RESULTS: In 5676 participants of the PREVEND (Prevention of Renal and Vascular End- Stage Disease) study 
cohort, EtG was measured in 24- hour urine samples and alcohol consumption questionnaires were administered. Participants 
were followed up for occurrence of first CVD and all- cause mortality. Cox proportional hazards regression models, adjusted 
for age, sex, and CVD risk factors, were fitted for self- reported consumption, divided into 5 categories: abstention, 1 to 4 
units/month (reference), 2 to 7 units/week, 1 to 3 units/day, and ≥4 units/day. Similar models were fitted for EtG, analyzed as 
both continuous and categorical variables. Follow- up times differed for CVD (8 years; 385 CVD events) and all- cause mortal-
ity (14 years; 724 deaths). For both self- reported alcohol consumption and EtG, nonsignificant trends were found toward J- 
shaped associations between alcohol consumption and CVD, with higher risk in the lowest (hazard ratio for abstention versus 
1–4 units/month, 1.42; 95% CI, 1.02–1.98) and highest drinking categories (hazard ratio for ≥4 units/day versus 1–4 units/
month, 1.11; 95% CI, 0.68–1.84). Neither self- report nor EtG was associated with all- cause mortality.
CONCLUSIONS: Comparable associations with CVD events and all- cause mortality were found for self- report and EtG. This 
argues for the validity of self- reported alcohol consumption in epidemiologic research.
Key Words: alcohol consumption ■ biomarker ■ cardiovascular disease ■ epidemiologic research ■ ethyl glucuronide
Alcohol consumption is among the most frequently studied risk factors for the development of chronic diseases.1–3 Observational research sug-
gests that the relation between alcohol consumption 
and cardiovascular disease (CVD) follows a J- shaped 
curve, indicating that moderate alcohol consumers 
have a lower cardiovascular risk compared with both 
abstainers and heavier drinkers.2,4–7 To date, the car-
dioprotective effects of moderate alcohol consumption 
remain debated, mainly because the data stem almost 
exclusively from observational studies, and a long- term 
randomized controlled trial is lacking. Even mendelian 
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randomization studies have failed to provide a single 
clear answer.8–10.
All observational studies of the association between 
alcohol and CVD have relied on self- report to estimate 
alcohol consumption. Self- report is a potentially un-
reliable source of information, with a tendency to un-
derestimate or misclassify consumption.11 Whether 
objectively measured alcohol consumption would 
yield similar results is unknown because reliable ob-
jective markers of habitual alcohol consumption are 
scarce, as most biomarkers either reflect short time 
periods12 or are not sufficiently specific.13 Urinary ethyl 
glucuronide (EtG) is a relatively new biomarker of alco-
hol consumption. It is a direct metabolite of ethanol, 
and thus a specific marker of alcohol consumption, 
with a detection time up to 72 hours after consump-
tion.14 EtG has been validated as a marker for alcohol 
consumption in controlled experiments.15–17 Moreover, 
a previous analysis of our cohort indicated that EtG ap-
pears to be linearly associated with self- reported habit-
ual consumption,18 with particularly high sensitivity for 
heavier drinking. Specificity was 92% and sensitivity 
was 66%, increasing up to 93% in the heavier drink-
ing categories.18 Hence, EtG appears to be a suitable 
marker to detect abstention and moderate to heavy 
drinking, in contrast with markers like carbohydrate- 
deficient transferrin (CDT), which tend to be elevated 
only in heavy drinking.19
In this study, we compared EtG as objective mea-
sure of habitual alcohol consumption with self- reported 
alcohol consumption in the association between alco-
hol consumption and CVD and all- cause mortality in 
a prospective population- based cohort. Moreover, by 
combining information on EtG, CDT, and self- report, 
we excluded participants with apparently misreported 




The PREVEND (Prevention of Renal and Vascular 
End- Stage Disease) study cohort is a Dutch cohort 
drawn from the general population of Groningen, The 
Netherlands, in 1997, originally established to moni-
tor the long- term development of cardiovascular and 
renal diseases in participants with microalbuminuria. 
Details of this study have been published elsewhere.20 
In short, after exclusion of insulin- dependent subjects 
and pregnant women, the cohort included 6000 partic-
ipants with a urinary albumin concentration >10 mg/L. 
A random sample of 2592 subjects without microal-
buminuria was also included. During the study period 
(1997–2013), participants attended 5 follow- up visits. 
Follow- up data on mortality were available up until 
January 2017. The PREVEND study was conducted in 
accordance with the Declaration of Helsinki guidelines 
and was approved by the Medical Ethics Committee 
of the University Medical Center Groningen. All par-
ticipants gave written informed consent. The data that 
support the findings of this study are available from the 
corresponding author upon reasonable request.
In the present study, we included participants 
who attended the second follow- up visit (N=6894; 
April 2001–December 2003), as urinary EtG concen-
trations were measured in urine samples that were 
collected during this period. The study period com-
prised the time from this visit until end of follow- up: 
from April 2001 until January 2017. Follow- up data 
for CVD events were only available until January 
2011, whereas information on all- cause mortality 
covered the entire study period. Participants without 
CLINICAL PERSPECTIVE
What Is New?
• This is the first study that includes ethyl glucu-
ronide as an objective alcohol biomarker, in ad-
dition to self-reported consumption, to examine 
and compare the associations of alcohol con-
sumption with cardiovascular disease and all-
cause mortality.
• Comparable associations with cardiovascular 
events and all-cause mortality were found for 
ethyl glucuronide and self-report.
What Are the Clinical Implications?
• Our findings support the reliability of self-re-
ported alcohol consumption in epidemiologic 
research.
• Objective biomarkers, like ethyl glucuronide, 
can serve as effective supportive tools to com-
plement self-report in the assessment of habit-
ual alcohol consumption.
Nonstandard Abbreviations and Acronyms
BMI  body mass index
CDT carbohydrate deficient transferrin
CVD cardiovascular disease
eGFR estimated glomerular filtration rate
EtG ethyl glucuronide
GGT γ glutamyl transferase
HDL-C  High-density lipoprotein cholesterol
PREVEND  Prevention of Renal and Vascular 
End-Stage Disease
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EtG measurements (N=60) or self- reported alco-
hol consumption (N=64) were excluded. Moreover, 
participants were excluded when urinary leukocyte 
measurements performed with Nephur- test+leuco 
sticks (Boehringer Mannheim, Mannheim, Germany) 
showed evidence for a urinary tract infection, defined 
as the presence of ≥75 leukocytes/μL (N=363) or 
≥50 erythrocytes/μL (N=196). Previous research has 
shown that bacterial contamination can influence EtG 
concentrations, which can lead to both false- positive 
and false- negative results.21,22
Finally, participants with prevalent CVD at baseline 
were excluded (N=443), as well as participants who 
did not contribute any follow- up time after the base-
line visit (N=48) or had missing values for ≥1 of the co-
variates (N=44). The analytical sample included 5676 
participants.
Assessment of Alcohol Consumption
Participants were asked to collect two 24- hour urine 
samples up to a maximum of 4 days before the base-
line visit after thorough oral and written instruction. 
Participants were asked to avoid heavy exercise and 
to postpone the urine collection in case of urinary 
tract infection, menstruation, or fever. Participants 
stored the samples temporarily at home at a tem-
perature of 4°C before the visit. At the visit, aliquots 
of these urine specimens were stored at −20°C. EtG 
concentrations were measured in the second 24- 
hour urine sample using the Thermo Scientific DRI 
Ethyl Glucuronide assay. It has a detection limit of 
100  ng/mL and has shown good agreement with 
established liquid chromatography/mass spectrom-
etry methods in detecting EtG.23 Intra- assay and 
interassay coefficients of variation were previously 
established at <1.7% and <2.2%, respectively.23 In 
accordance with previous research,24–26 we used a 
cutoff value of ≥100 ng/mL to define positivity for in-
tentional alcohol consumption.
Self- reported alcohol consumption was mea-
sured with a single question assessing the combined 
quantity- frequency consumption on the participants’ 
average usual alcohol consumption at baseline and 
the first 2 follow- up visits. Participants were asked 
to choose 1 of the following categories: abstention 
(no alcohol consumption), 1 to 4 units/month, 2 to 7 
units/week, 1 to 3 units/day, or ≥4 units/day. In The 
Netherlands, a standard serving of an alcoholic bever-
age contains approximately 10 g of alcohol.27 We as-
sessed whether alcohol consumption remained stable 
over time, comparing self- reported alcohol consump-
tion at baseline with self- reported consumption at the 
second follow- up visit. Alcohol consumption was con-
sidered stable if a participant did not shift >1 category 
during total follow- up.
Transferrin and CDT concentrations were mea-
sured in serum. Transferrin was analyzed by immu-
noturbidimetric assay on a Cobas analyzer (Roche 
Diagnostics GmbH, Mannheim Germany), whereas 
CDT was analyzed on a BNII nephelometer (Siemens 
Healthcare GmbH, Marburg, Germany). The trans-
ferrin assay is standardized against the reference 
preparation of the Institute for Reference Materials 
and Measurements BCR470/CRM470. The obtained 
intra- assay and interassay coefficients of variation 
were 1.4 to 1.9 at a level of 1.8 g/L and 1.8% to 1.8% 
at a level of 2.8 g/L. The detection limit of the assay 
is 0.1 g/L.
Reference values for CDT were 28.1 to 76.0 mg/L 
CDT (1st–99th percentile). Intra- assay and interassay 
coefficients of variation were 2.8% to 4.9% and 1.5% to 
7.6%, respectively, depending on the level measured. 
The detection limit for CDT was 20 mg/L. The percent-
age CDT was calculated by dividing the CDT concen-
tration on the total transferrin concentration. Reference 
values for percentage CDT there were 1.19% to 2.47% 
CDT (1st–99th percentile).28
Primary and Secondary End Points
The primary end point was time to first CVD event. 
This was composed of cardiac events, cerebrovas-
cular events, and peripheral vascular events. Cardiac 
events included myocardial infarction, ischemic 
heart disease, coronary artery bypass grafting, per-
cutaneous transluminal coronary intervention, and 
death from previously mentioned conditions. We 
included the following cerebrovascular events: in-
tracranial hemorrhage, subarachnoid hemorrhage, 
ischemic stroke, transient cerebral ischemia, occlu-
sion of precerebral arteries, and death from these 
conditions. Peripheral events included bypass sur-
gery of the peripheral arteries, aneurysm, and death 
from these conditions. Occurrences of CVD events 
were obtained from PRISMANT, the Dutch National 
Registry of hospital discharge diagnoses.29 The sec-
ondary end point was all- cause mortality, which was 
ascertained by data linkage with the Dutch Central 
Bureau of Statistics. Data were coded according to 
the  International Classification of Diseases, Tenth 
Revision (ICD-10). Mortality was categorized into 
CVD, cancer, or “other causes” by ICD-10 coding.
Covariates
During the baseline visit, participants were asked to com-
plete questionnaires about lifestyle factors, family history 
for CVD, medical history, and medication use. Education 
level was self- reported on the basis of highest ascertain-
ment and stratified according to 3 categories: low (pri-
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middle (higher secondary education), and high (higher 
vocational education and university). Smoking status 
was categorized into the following categories: (1) “never 
smoking,” (2) “former smoking,” (3) “<6 cigarettes/day,” 
(4) “>6 to 20 cigarettes/day,” and (5) “>20 cigarettes/
day.” Physical activity was measured as self- reported 
frequency of exercise and was categorized into 3 cat-
egories: (1) “no/hardly,” (2) “less than once a week,” and 
(3) “twice or more times a week.” Body mass index (BMI) 
was calculated as measured weight in kilograms divided 
by the square of height in meters and was categorized 
into 5 categories: (1) “BMI <20 kg/m2,” (2) “BMI 20 to 22.9 
kg/m2,” (3) “BMI 23 to 24.9 kg/m2,” (4) “BMI 25 to 29.9 kg/
m2,” and (5) “BMI >30 kg/m2.”
We defined type 2 diabetes mellitus (T2DM) as 
self- reported T2DM, use of antidiabetic medication, 
or fasting blood glucose at baseline ≥7.0  mmol/L.30 
Hypertension at baseline was defined as self- reported 
hypertension, use of antihypertensive medication, or 
a blood pressure at baseline of >140 mm Hg systolic 
or >90 mm Hg diastolic.31 Hypercholesterolemia was 
defined as self- reported hypercholesterolemia, use of 
cholesterol- lowering drugs, or a total cholesterol level 
at baseline of >6.5 mmol/L.32 As a measure of kidney 
function, estimated glomerular filtration rate (eGFR) 
was calculated using the combined creatinine–cys-
tatin C–based Chronic Kidney Disease Epidemiology 
Collaboration equation.33
Statistical Analysis
All statistical analyses were performed using IBM 
SPSS 25.0 for Windows and R studio version 3.4.1. 
Descriptive statistics were used to assess the distri-
bution of the data. Because eGFR was the only vari-
able with considerable missingness (N=288 [5.0%]), 
we imputed missing values with the mean (93.3 mL/
min per 1.73 m2). We excluded small numbers of 
missing values (<1.1%) for T2DM, hypertension, 
smoking, and physical activity. We compared self- 
reported alcohol consumption and EtG, high- density 
lipoprotein cholesterol, and CDT using Spearman 
correlation coefficients.
We fitted 3 adjusted Cox proportional hazards 
models to study the associations of EtG and self- 
reported alcohol consumption with cardiovascular 
outcomes, all- cause mortality, and cause- specific 
mortality. We additionally restricted the analyses to 
cardiac outcomes. Urinary EtG was assessed as 
both a continuous variable on a natural logarithmic 
scale, excluding undetectable EtG, and a categor-
ical variable, which was divided into undetectable 
EtG concentrations (category 1) and quintiles of de-
tectable EtG concentrations. The second category 
was considered the reference category to take light 
drinkers as the referent. As sensitivity analyses, we 
additionally assessed total excretion of EtG (ie, EtG 
concentration×urine volume) and EtG/urinary creati-
nine ratio to correct for urine dilution. Self- reported 
alcohol consumption was analyzed as a categorical 
variable, using the 5 consumption categories: ab-
stention, 1 to 4 units/month, 2 to 7 units/week, 1 to 
3 units/day, and ≥4 units/day. The category 1 to 4 
units/month was considered the reference category. 
Model 1 was adjusted for age and sex. Model 2 was 
adjusted for model 1 and smoking, BMI, physical 
activity, education level, and family history of CVD. 
Model 3 contained the same covariates as model 
2, but additionally adjusted for T2DM, hypertension, 
hypercholesterolemia, and kidney function, as these 
factors were also considered potential mediators in 
the causal pathway. Age, sex, and eGFR are poten-
tial effect modifiers for the association between EtG 
concentrations and CVD and all- cause mortality.24–26 
Therefore, these variables and their interaction terms 
with EtG were separately entered in the model. When 
suggestive interaction terms (P<0.10) were identified, 
analyses were stratified accordingly.
We plotted Martingale residuals against age and 
kidney function to test which functional form of these 
covariates best fitted the model. We used scaled 
Schoenfeld residuals to test the proportional hazards 
assumption. Results are presented as hazard ratios 
with 95% CIs. We tested for trend by adding the linear 
term in the model. To assess the presence of nonlin-
ear relationships, we entered the quadratic and cubic 
terms of EtG with the linear term. If nonlinear relations 
were found (P<0.05 for quadratic/cubic term), splines 
were applied to fit different polynomials.
Sensitivity Analyses
As we had multiple measures of self- reported alcohol 
consumption, we performed a sensitivity analysis ex-
cluding participants who reported inconsistent alcohol 
consumption over time, defined as a shift of >1 cat-
egory (N=212). As a second sensitivity analysis, we 
additionally fitted the models with simple time- varying 
alcohol consumption, using the self- reported alcohol 
consumption of the baseline visit and the 2 follow- up 
rounds.
To address misclassification by self- report, we 
combined information on EtG and CDT concen-
trations and self- reported alcohol consumption to 
exclude participants with misreported alcohol con-
sumption. We performed a sensitivity analysis ex-
cluding participants with discrepant values for EtG 
and self- reported consumption, and for CDT and 
self- reported consumption. To do so, we regressed 
EtG concentration on self- reported alcohol con-
sumption and excluded participants with the highest 
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excluded those participants who reported ≥1 glass 
of alcohol a day, but had a discrepant EtG concen-
tration <100  ng/mL (N=126). Likewise, self- reported 
abstainers with EtG concentrations >100 ng/mL were 
excluded (N=102). Finally, the 5% highest residuals 
from the regression of CDT on self- report were ex-
cluded (N=234). Because heavy drinkers are most 
prone to underreport their alcohol consumption,34 we 
additionally excluded participants with CDT values 




Among the 5676 eligible participants, mean age at 
baseline was 52.9 (SD, 11.8) years, and 51.2% were 
men. Urinary EtG was detected in 52.2% of the 
samples, consistent with intentional recent alcohol 
consumption. Urinary EtG concentrations ranged 
from 0 to 531 900 ng/mL. Abstention from alcohol 
was reported by 24% of the participants. In general, 
participants without detectable EtG concentrations 
were more often women, were slightly older, and re-
ported lower levels of education and more comor-
bidities, particularly T2DM (Table 1). We observed a 
similar pattern when self- reported alcohol consump-
tion categories were used (Table S1). Self- reported 
consumption categories were significantly correlated 
with EtG (rs=0.68; P<0.001), high- density lipoprotein 
cholesterol (rs=0.11; P<0.001), and CDT (rs=0.25; 
P<0.001).
Median follow- up time from baseline until January 
2011 was 8.3  years (25–75 percentile, 7.8–8.9 
years). In this period, 385 (6.8%) cardiovascular 
events occurred. Most events were myocardial in-
farctions (N=102 [1.8%]) or ischemic heart disease 
(N=77 [1.4%]). Follow- up time for all- cause mortal-
ity was available from baseline until January 2017, 
with a median follow- up time of 14.1  years (25–75 
percentile, 11.6–14.7 years). A total of 724 (12.8%) 
deaths occurred, of which 156 (2.7%) were cardio-
vascular deaths, 354 (6.2%) were cancer related, 212 
(3.7%) were otherwise specified, and 2 (0.03%) were 
unknown.
Figure  1. Scatterplot of alcohol consumption categories and ethyl glucuronide (EtG) 
concentrations for 5676 PREVEND (Prevention of Renal and Vascular End- Stage Disease) 
study participants. 
Exclusion of participants with misreported consumption (N=667), on the basis of discrepancies 
between self- reported consumption and concentrations of biomarkers EtG and carbohydrate- 
deficient transferrin (CDT). The lowest and highest 2.5% residuals of the regression between EtG and 
self- reported consumption and the highest 5% residuals of the regression between CDT and self- 
report were excluded. Moreover, participants who reported abstention, but with EtG concentrations 
>100 ng/mL, and vice versa were excluded. In addition, heavy drinkers were excluded, on the basis 
of CDT values. Alcohol consumption categories: 0, abstention; 1, 1 to 4 units/month; 2, 2 to 7 units/
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Alcohol and CVD
The association between self- reported alcohol con-
sumption and CVD appeared to be nonlinear, with a 
higher CVD risk for the abstention category compared 
with the reference category of 1 to 4 units/month and 
a trend toward a higher risk in the heavier alcohol 
consumption categories. Adjustment for confounders 
slightly attenuated the associations (Table 2). A similar 
trend was found when EtG was used as the exposure 
measure: the lowest and highest categories appeared 
to be associated with a higher CVD risk compared 
with the other categories (Table  3). We observed a 
nonlinear association when ln EtG was tested continu-
ously (P for cubic term=0.04) (Figure 2). There was no 
effect modification by sex, age, or eGFR. Restricting 
the analyses to exclusively cardiac events (N=289) 
yielded similar results (data not shown). The shape 
of the association remained similar for both total EtG 
excretion and EtG/creatinine ratio but did not reach 
statistical significance (data not shown).
Alcohol and All- Cause Mortality
No significant associations were found between self- 
reported alcohol consumption and all- cause mortality 
or between EtG and all- cause mortality (Tables 2 and 
3). Stratification by cause of death did not alter these 
results (data not shown). No effect modification by age, 
sex, or eGFR was found. Similar results were found 
when EtG was assessed as total EtG excretion and 
EtG/creatinine ratio.
Sensitivity Analyses
Exclusion of participants who reported unstable alcohol 
consumption over time, defined as a shift in >1 alcohol 
consumption category (N=212), did not lead to different 
associations (Table 4 and Table S2). Inclusion of a time- 
varying term for alcohol consumption demonstrated a 
lower mortality risk in the 1 to 3 units/day group com-
pared with the 1 to 4 units/month group, which appeared 
to be driven by mortality other than cardiovascular or 
Table 1. Baseline Characteristics of 5676 PREVEND Study Participants, by EtG Category
Characteristic
EtG Concentration at Baseline, Percentiles
Undetectable 
EtG  
(<100 ng/mL) Quintiles of Detectable EtG (≥100 ng/mL)
Category 1 Category 2 Category 3 Category 4 Category 5 Category 6
N (%) 2716(47.9) 592(10.4) 593(10.4) 591(10.4) 592(10.4) 592(10.4)
Information on EtG
EtG level 0±0 350±186 1320±371 3519±911 8936±2397 51 660±58 858
EtG level 0 (0; 0) 320 (185; 489) 1281 (989; 1656) 3533 (2771; 4313) 8391 (6996; 10 761) 33 212 (18 842; 53 954)
Range of EtG level 0 100 to 635 736 to 1971 1974 to 5223 5232 to 14 272 14 284 to 531 900
Men 1206 (44.4) 305 (51.5) 317 (53.5) 327 (55.3) 342 (57.8) 409 (69.1)
Age, y 53.4±12.4 52.2±12.3 51.7±11.5 52.4±10.4 52.9±11.2 52.8±10.0
BMI, kg/m2 26.6 (24.0; 29.6) 25.9 (23.3; 28.7) 25.3 (23.2; 27.8) 25.5 (23.3; 28.4) 25.5 (23.3; 28.4) 25.7 (23.4; 28.4)
Smoking
Never smokers 953 (35.1) 203 (34.3) 164 (27.7) 150 (25.4) 129 (21.8) 77 (13.0)
Educational level
Low 1377 (50.7) 215 (36.3) 205 (34.6) 195 (33.0) 206 (34.8) 198 (33.4)
Physical activity
No exercise 481 (17.7) 76 (12.8) 65 (11.0) 71 (12.0) 74 (12.5) 91 (15.4)
Comorbidities
Diabetes mellitus 191 (7.0) 29 (4.9) 25 (4.2) 18 (3.0) 31 (5.2) 28 (4.7)
Hypertension 911 (33.5) 166 (28.0) 150 (25.3) 154 (26.1) 176 (29.7) 196 (33.1)
Hypercholesterolemia 917 (33.8) 212 (35.8) 187 (31.5) 201 (34.0) 214 (36.1) 266 (45.0)
Family history of CVD 990 (36.5) 212 (35.8) 184 (31.0) 203 (34.3) 185 (31.3) 211 (35.6)
Measurements at baseline
CDT, % of total transferrin 1.4 (1.3; 1.7) 1.5 (1.3; 1.7) 1.5 (1.3; 1.8) 1.6 (1.3; 1.8) 1.6 (1.4; 1.9) 1.8 (1.5; 2.3)
HDL- C, mg/dL 46.7±11.5 48.5±12.3 48.6±11.8 50.1±12.1 50.4±13.2 51.4±13.8
eGFR, mL/min per 1.73 m2 91.5±16.7 94.4±16.3 95.0±15.4 94.2±14.9 94.2±15.4 96.4±14.4
Values represent numbers (percentages), means±SDs, or medians (25th–75th percentiles). Unit for EtG is ng/mL. BMI indicates body mass index; CDT, 
carbohydrate- deficient transferrin; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EtG, ethyl glucuronide; HDL- C, high density 
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cancer- related mortality (Table S3). Finally, combining 
self- report and the biomarkers EtG and CDT into one 
measure and excluding the heavy drinkers did not signif-
icantly alter the associations between alcohol consump-
tion and CVD and all- cause mortality (Table 4).
DISCUSSION
In this prospective cohort study, the association be-
tween alcohol consumption and CVD tended to be 
similar when EtG concentrations and self- report were 
used as measures of alcohol consumption. Although 
not statistically significant, the association between al-
cohol and CVD appeared to be nonlinear, with a lower 
risk for light- to- moderate drinkers compared with ab-
stainers and heavy drinkers. We observed no associa-
tions between alcohol consumption measured by either 
EtG or self- report and all- cause mortality. Exclusion of 
participants who reported unstable alcohol consump-
tion over time or had discrepant values for EtG/CDT and 
self- report did not alter our findings. Overall, our results 
support the reliability of self- reported consumption as a 
measure of habitual alcohol consumption.
Strengths and Limitations
To our knowledge, ours is the first long- term prospec-
tive cohort study to include EtG or any other direct 




P for TrendAbstention (N= 1366) 1 to 4/mo (N=960) 2 to 7/wk (N=1830) 1 to 3/d (N=1269) ≥4/d (N=251)
CVD events, N (%) 115 (8) 52 (5) 105 (6) 90 (7) 24 (10)
Model 1 1.56 (1.12–2.17)* Reference 1.15 (0.82–1.61) 1.20 (0.85–1.69) 1.44 (0.88–2.34) 0.23
Model 2 1.43 (1.03–1.99)* Reference 1.12 (0.80–1.57) 1.22 (0.86–1.72) 1.28 (0.78–2.11) 0.42
Model 3 1.42 (1.02–1.98)* Reference 1.09 (0.78–1.52) 1.11 (0.79–1.58) 1.11 (0.68–1.84) 0.16
All- cause mortality, N (%) 204 (15) 118 (12) 198 (11) 165 (13) 39 (16)
Model 1 1.18 (0.94–1.48) Reference 1.14 (0.91–1.44) 1.12 (0.88–1.42) 1.27 (0.88–1.84) 0.88
Model 2 1.10 (0.87–1.38) Reference 1.08 (0.86–1.36) 1.04 (0.81–1.32) 1.02 (0.70–1.48) 0.66
Model 3 1.06 (0.84–1.34) Reference 1.06 (0.84–1.34) 1.01 (0.79–1.29) 0.97 (0.67–1.41) 0.67
Data are given as hazard ratios (95% CIs) for alcohol consumption categories vs the reference category with CVD events and all- cause mortality. Model 1, 
adjusted for age (years) and sex. Model 2, adjusted for model 1, smoking, education, physical activity, body mass index (categories), and parental history of 
CVD. Model 3, adjusted for model 2, hypertension, hypercholesterolemia, diabetes mellitus, and renal function (estimated glomerular filtration rate). Alcohol 
consumption categories are displayed in standard units per time period; 1 standard unit contains 10 g of alcohol. CVD indicates cardiovascular disease; and 
PREVEND, Prevention of Renal and Vascular End- Stage Disease.
*P<0.05.

















(N=592) P for Trend
CVD events, N (%) 205 (8) 37 (6) 22 (4) 29 (5) 42 (7) 50 (8) CVD events, N (%)
Model 1 1.18 (0.83–1.68) Reference 0.58 (0.34–0.98)* 0.80 (0.49–1.31) 1.03 (0.66–1.61) 1.25 (0.81–1.91)  Model 1
Model 2 1.14 (0.80–1.62) Reference 0.58 (0.34–0.99)* 0.83 (0.51–1.35) 1.04 (0.67–1.62) 1.13 (0.74–1.75)  Model 2
Model 3 1.16 (0.82–1.65) Reference 0.60 (0.35–1.02) 0.81 (0.50–1.32) 1.03 (0.66–1.60) 1.06 (0.69–1.63)  Model 3
All- cause mortality, N (%) 358 (13) 79 (13) 57 (10) 68 (12) 80 (14) 82 (14) All- cause 
mortality, N (%)
Model 1 0.91 (0.72–1.17) Reference 0.76 (0.54–1.07) 1.01 (0.73–1.39) 0.97 (0.71–1.33) 1.16 (0.85–1.58)  Model 1
Model 2 0.91 (0.71–1.16) Reference 0.75 (0.53–1.05) 1.01 (0.73–1.40) 0.95 (0.70–1.30) 0.95 (0.69–1.30)  Model 2
Model 3 0.89 (0.70–1.14) Reference 0.75 (0.53–1.06) 1.01 (0.73–1.41) 0.94 (0.69–1.29) 0.93 (0.67–1.27)  Model 3
Data are given as hazard ratios (95% CIs) for EtG categories vs the reference category with CVD events and all- cause mortality. Model 1, adjusted for age (years) 
and sex. Model 2, adjusted for model 1, smoking, education, physical activity, body mass index (categories), and parental history of CVD. Model 3, adjusted for 
model 2, hypertension, hypercholesterolemia, diabetes mellitus, and renal function (estimated glomerular filtration rate). CVD indicates cardiovascular disease; 
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biomarker of alcohol as a measure of habitual alco-
hol consumption in causative research. This enabled 
us to assess the impact of probable misclassification 
in self- reported consumption on its associations 
with CVD and mortality, robust to several sensitivity 
analyses.





TrendAbstention 1–4/mo 2–7/wk 1–3/d ≥4/d
CVD events
Main analysis model 3 1.42 (1.02–1.98)* Reference 1.09 (0.78–1.52) 1.11 (0.79–1.58) 1.11 (0.68–1.84) 0.16
Exclusion of unstable consumption (n=5464) 1.47 (1.05–2.06)* Reference 1.15 (0.81–1.61) 1.19 (0.84–1.70) 1.16 (0.69–1.94) 0.22
Time- varying consumption (n=5676) 1.02 (0.75–1.38) Reference 0.75 (0.54–1.04) 0.93 (0.67–1.28) 0.79 (0.47–1.33) 0.25
Exclusion of misreported consumption (n=5068) 1.52 (1.08–2.14)* Reference 1.09 (0.77–1.53) 1.12 (0.78–1.62) 1.11 (0.63–1.96) 0.07
Exclusion of misreported consumption+heavy 
drinkers (n=5009)
1.52 (1.08–2.14)* Reference 1.09 (0.77–1.53) 1.14 (0.79–1.65) 1.10 (0.61–1.98) 0.08
All- cause mortality
Main analysis model 3 1.06 (0.84–1.34) Reference 1.06 (0.84–1.34) 1.01 (0.79–1.29) 0.97 (0.67–1.41) 0.67
Exclusion of unstable consumption (n=5464) 1.05 (0.83–1.33) Reference 1.07 (0.84–1.35) 0.99 (0.77–1.27) 0.97 (0.66–1.42) 0.64
Time- varying consumption (n=5676) 0.86 (0.69–1.07) Reference 0.86 (0.68–1.07) 0.77 (0.61–0.98)* 0.80 (0.54–1.20) 0.06
Exclusion of misreported consumption (n=5068) 1.10 (0.86–1.39) Reference 1.06 (0.83–1.34) 1.03 (0.80–1.34) 1.02 (0.67–1.56) 0.69
Exclusion of misreported consumption+heavy 
drinkers (n=5009)
1.10 (0.86–1.39) Reference 1.05 (0.83–1.33) 1.01 (0.78–1.31) 1.05 (0.68–1.63) 0.64
Data are given as hazard ratios (95% CIs) for alcohol consumption categories vs the reference category with CVD events and all- cause mortality. 
Models are adjusted for age (years), sex, smoking, education, physical activity, body mass index (categories), and parental history of CVD, hypertension, 
hypercholesterolemia, diabetes mellitus, and renal function (estimated glomerular filtration rate). Alcohol consumption categories are displayed in standard units 
per time period; 1 standard unit contains 10 g of alcohol. CVD indicates cardiovascular disease.
*P<0.05.
Figure  2. Continuous association between urinary ethyl glucuronide (EtG) and 
cardiovascular disease in 5676 PREVEND (Prevention of Renal and Vascular End- Stage 
Disease) study participants. 
Spline is adjusted for age (years), sex, smoking, education, physical activity, body mass index 
(categories), and parental history of cardiovascular disease, hypertension, hypercholesterolemia, 
diabetes mellitus, and renal function (estimated glomerular filtration rate). The histogram 
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One limitation of this study was that the event rate was 
relatively low. As a result, the precision of our estimates 
was insufficient to exclude plausibly sized effects on 
mortality. Furthermore, information on self- reported al-
cohol consumption was derived from a self- administered 
questionnaire that yielded limited information on the 
pattern of alcohol intake. Because the associations of 
alcohol consumption with CVD and mortality are both 
markedly affected by the pattern of drinking,7 we may 
have missed important associations of the quantity or 
frequency of alcohol intake with these outcomes.
Finally, urinary EtG as a marker also has its limitations: 
although it has a much longer detection window than 
most other direct biomarkers, EtG still is a short- term 
biomarker, covering only the 72 hours after consump-
tion. Therefore, light drinkers in particular are easily mis-
classified and discriminating between abstainers and 
light drinkers can be problematic. Repeated sampling 
would decrease the misclassification of light drinkers, 
but is unlikely to be readily feasible in large- scale pop-
ulation research. EtG measured in hair might provide a 
better alternative, as this represents a more long- term 
measure of consumption, lasting several months.35 
However, EtG in hair provides useful qualitative but not 
necessarily quantitative information.36
Previous Research
To date, few studies have included indirect alcohol 
biomarkers in examining the associations between 
alcohol and disease. Jousilahti et  al37 compared 
CDT, γ glutamyl transferase (GGT), and self- report 
with coronary heart disease and found an inverse 
association for CDT, but a positive association for 
GGT with coronary heart disease. Self- reported con-
sumption showed a borderline inverse association, 
which was attenuated after adjustment for confound-
ers. The authors pointed out that self- reported levels 
of alcohol consumption in this study were low. Zatu 
et al38 studied CDT, GGT, and self- reported alcohol 
consumption with mortality. Only GGT was signifi-
cantly positively associated with all- cause and car-
diovascular mortality. Both studies emphasize that 
other factors than alcohol may influence these indi-
rect markers. Indeed, other studies examined the as-
sociation between GGT and coronary heart disease 
and confirmed that there is an independent mecha-
nism linking serum GGT to coronary heart disease, 
which is also present in abstainers.39,40 By contrast, 
direct markers, such as EtG, are metabolites of the 
alcohol molecule and therefore specific for alcohol 
consumption.
In our study, we identified trends toward a J- shaped 
association with CVD, but could not definitively repli-
cate previous observational studies that found a non-
linear relation between alcohol and CVD.2,5–7 Moreover, 
neither EtG nor self- reported consumption was asso-
ciated with all- cause mortality, in contrast to previous 
studies that did find associations between alcohol and 
all- cause mortality and cause- specific mortality.7,41,42 
This could have been because of the limited power of 
our study. In addition, the contribution of cardiovascu-
lar deaths to overall mortality was relatively small, and 
the association between alcohol and all- cause mor-
tality is generally driven by cardiovascular mortality.42 
Nevertheless, we observed similar results with EtG 
and self- report, as well as with self- report corrected 
for misclassification.
The consistency of our results across several mea-
surement methods implies that findings from previous 
studies using self- report exclusively as a measure for 
alcohol consumption are unlikely to be heavily distorted 
by the subjectivity of self- report. At the same time, our 
results demonstrate the feasibility of incorporating 
urinary EtG in studies of populations in which self- 
report may be less reliable than the PREVEND study. 
Measurement of urinary EtG is inexpensive, easy, and 
noninvasive for the participant and therefore may be 
feasibly incorporated into even large- scale research.
In conclusion, self- reported alcohol consumption 
shows a similar association between alcohol consump-
tion and CVD when compared with an objective mea-
sure of alcohol consumption. Moreover, these findings 
are consistent when the measures are combined to 
minimize misclassification. This argues for the validity 
of self- report; however, objective biomarkers can serve 
as effective supportive tools to complement self- report 
in the assessment of habitual alcohol consumption.
ARTICLE INFORMATION
Received September 4, 2019; accepted February 6, 2020.
Affiliations
From the Julius Center for Health Sciences and Primary Care, University 
Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands 
(I.A.T.v.d.L., I.C.S., D.E.G., J.W.J.B.); Julius Clinical, Zeist, The Netherlands 
(I.A.T.v.d.L., I.C.S. D.E.G.); Division of Nephrology, Department of Internal 
Medicine (L.M.K., S.J.L.B.), Department of Clinical Pharmacy and 
Pharmacology (D.J.T.), and Department of Laboratory Medicine (J.E.K.-R., 
A.C.M.K.), University of Groningen, University Medical Center Groningen, 
The Netherlands; Department of Pharmaceutical analysis, University of 
Groningen, Groningen Research Institute of Pharmacy, The Netherlands 
(D.J.T.); Departments of Nephrology (A.J.v.B.) and Epidemiology and 
Biostatistics (S.v.O., J.W.J.B.), Amsterdam Cardiovascular Sciences 
Research Institute, Amsterdam University Medical Center, location VU 
Medical Center Amsterdam, The Netherlands; Department of Medicine, 
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 
MA (K.J.M.).
Sources of Funding
This work was financially support by the European Union Joint Programming 
Initiative “A Healthy Diet for a Healthy Life” on Biomarkers BioNH FOODBALL 
(grant 529051002), The Food Biomarkers Alliance. Drs van de Luitgaarden 






 http://ahajournals.org by on M
arch 30, 2020
J Am Heart Assoc. 2020;9:e014324. DOI: 10.1161/JAHA.119.014324 10




 1. Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke 
M. Alcohol as a risk factor for liver cirrhosis: a systematic review and 
meta- analysis. Drug Alcohol Rev. 2010;29:437–445.
 2. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association 
of alcohol consumption with selected cardiovascular disease out-
comes: a systematic review and meta- analysis. BMJ. 2011;342:d671.
 3. Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom 
AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR, 
et al. Alcohol and breast cancer in women: a pooled analysis of cohort 
studies. JAMA. 1998;279:535–540.
 4. Merry AH, Boer JM, Schouten LJ, Feskens EJ, Verschuren WM, Gorgels 
AP, van den Brandt PA. Smoking, alcohol consumption, physical activ-
ity, and family history and the risks of acute myocardial infarction and 
unstable angina pectoris: a prospective cohort study. BMC Cardiovasc 
Disord. 2011;11:13.
 5. Mukamal KJ, Chung H, Jenny NS, Kuller LH, Longstreth WT Jr, 
Mittleman MA, Burke GL, Cushman M, Psaty BM, Siscovick DS. 
Alcohol consumption and risk of coronary heart disease in older 
adults: the Cardiovascular Health Study. J Am Geriatr Soc. 2006;54: 
30–37.
 6. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner 
B, Stampfer MJ. Prospective study of alcohol consumption and risk of 
coronary disease in men. Lancet. 1991;338:464–468.
 7. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, 
Paige E, Paul DS, Sweeting M, Burgess S, et al; Emerging Risk Factors 
Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk 
thresholds for alcohol consumption: combined analysis of individual- 
participant data for 599 912 current drinkers in 83 prospective studies. 
Lancet. 2018;391:1513–1523.
 8. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-
Merino D, Dehghan A, Trompet S, Wong A, et al. Association between 
alcohol and cardiovascular disease: Mendelian randomisation analysis 
based on individual participant data. BMJ. 2014;349:g4164.
 9. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, 
Chen Y, Dong C, Hu R, et al. Conventional and genetic evidence on 
alcohol and vascular disease aetiology: a prospective study of 500 000 
men and women in China. Lancet. 2019;393:1831–1842.
 10. Zhang LL, Wang YQ, Fu B, Zhao SL, Kui Y. Aldehyde dehydrogenase 2 
(ALDH2) polymorphism gene and coronary artery disease risk: a meta- 
analysis. Genet Mol Res. 2015;14:18503–18514.
 11. Stockwell T, Donath S, Cooper-Stanbury M, Chikritzhs T, Catalano P, 
Mateo C. Under- reporting of alcohol consumption in household sur-
veys: a comparison of quantity- frequency, graduated- frequency and 
recent recall. Addiction. 2004;99:1024–1033.
 12. Savola O, Niemela O, Hillbom M. Blood alcohol is the best indicator of 
hazardous alcohol drinking in young adults and working- age patients 
with trauma. Alcohol. 2004;39:340–345.
 13. Niemela O. Biomarkers in alcoholism. Clin Chim Acta. 2007;377: 
39–49.
 14. Kissack JC, Bishop J, Roper AL. Ethylglucuronide as a biomarker for 
ethanol detection. Pharmacotherapy. 2008;28:769–781.
 15. Borucki K, Schreiner R, Dierkes J, Jachau K, Krause D, Westphal S, 
Wurst FM, Luley C, Schmidt-Gayk H. Detection of recent ethanol intake 
with new markers: comparison of fatty acid ethyl esters in serum and of 
ethyl glucuronide and the ratio of 5- hydroxytryptophol to 5- hydroxyindole 
acetic acid in urine. Alcohol Clin Exp Res. 2005;29:781–787.
 16. Dahl H, Stephanson N, Beck O, Helander A. Comparison of urinary ex-
cretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol. 
2002;26:201–204.
 17. Helander A, Bottcher M, Fehr C, Dahmen N, Beck O. Detection times 
for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during 
alcohol detoxification. Alcohol. 2009;44:55–61.
 18. van de Luitgaarden IAT, Beulens JWJ, Schrieks IC, Kieneker LM, 
Touw DJ, van Ballegooijen AJ, van Oort S, Grobbee DE, Bakker SJL. 
Urinary ethyl glucuronide can be used as a biomarker of habitual 
alcohol consumption in the general population. J Nutr. 2019;149: 
2199–2205.
 19. Marques P, Tippetts S, Allen J, Javors M, Alling C, Yegles M, Pragst F, 
Wurst F. Estimating driver risk using alcohol biomarkers, interlock blood 
alcohol concentration tests and psychometric assessments: initial de-
scriptives. Addiction. 2010;105:226–239.
 20. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, 
De Jong PE. Urinary albumin excretion is associated with renal func-
tional abnormalities in a nondiabetic population. J Am Soc Nephrol. 
2000;11:1882–1888.
 21. Helander A, Dahl H. Urinary tract infection: a risk factor for false- 
negative urinary ethyl glucuronide but not ethyl sulfate in the detection 
of recent alcohol consumption. Clin Chem. 2005;51:1728–1730.
 22. Walsham NE, Sherwood RA. Ethyl glucuronide. Ann Clin Biochem. 
2012;49:110–117.
 23. Bottcher M, Beck O, Helander A. Evaluation of a new immunoassay for 
urinary ethyl glucuronide testing. Alcohol. 2008;43:46–48.
 24. Ferraguti G, Ciolli P, Carito V, Battagliese G, Mancinelli R, Ciafre S, 
Tirassa P, Ciccarelli R, Cipriani A, Messina MP, et al. Ethylglucuronide 
in the urine as a marker of alcohol consumption during pregnancy: 
comparison with four alcohol screening questionnaires. Toxicol Lett. 
2017;275:49–56.
 25. Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, Nogueira C, 
Shi J, Dziura JD, Petrakis IL, O’Malley SS. Ethyl glucuronide and ethyl 
sulfate assays in clinical trials, interpretation, and limitations: results of 
a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin 
Exp Res. 2014;38:2056–2065.
 26. Wurst FM, Wiesbeck GA, Metzger JW, Weinmann W. On sensitivity, 
specificity, and the influence of various parameters on ethyl glucuronide 
levels in urine: results from the WHO/ISBRA study. Alcohol Clin Exp Res. 
2004;28:1220–1228.
 27. Kromhout D, Spaaij CJ, de Goede J, Weggemans RM. The 2015 Dutch 
food- based dietary guidelines. Eur J Clin Nutr. 2016;70:869–878.
 28. Delanghe JR, Helander A, Wielders JP, Pekelharing JM, Roth HJ, 
Schellenberg F, Born C, Yagmur E, Gentzer W, Althaus H. Development 
and multicenter evaluation of the N latex CDT direct immunonephelo-
metric assay for serum carbohydrate- deficient transferrin. Clin Chem. 
2007;53:1115–1121.
 29. Stricker BH, Herings RM. Plea for the retention of the Dutch National 
Medical Registration (LMR) to provide reliable information regarding pub-
lic health and healthcare. Ned Tijdschr Geneeskd. 2006;150:1916–1917.
 30. Authors/Task Force Members, Ryden L, Grant PJ, Anker SD, Berne 
C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, 
et al. ESC guidelines on diabetes, pre- diabetes, and cardiovascular 
diseases developed in collaboration with the EASD: the Task Force on 
diabetes, pre- diabetes, and cardiovascular diseases of the European 
Society of Cardiology (ESC) and developed in collaboration with the 
European Association for the Study of Diabetes (EASD). Eur Heart J. 
2013;34:3035–3087.
 31. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, 
Cooney MT, Corra U, Cosyns B, Deaton C, et al. 2016 European guide-
lines on cardiovascular disease prevention in clinical practice: The Sixth 
Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice 
(constituted by representatives of 10 societies and by invited experts): 
developed with the special contribution of the European Association 
for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 
2016;37:2315–2381.
 32. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer 
G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Estimation 
of ten- year risk of fatal cardiovascular disease in Europe: the SCORE 
project. Eur Heart J. 2003;24:987–1003.
 33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene 
T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomer-
ular filtration rate from serum creatinine and cystatin C. N Engl J Med. 
2012;367:20–29.
 34. Poikolainen K. Underestimation of recalled alcohol intake in relation to 
actual consumption. Br J Addict. 1985;80:215–216.
 35. Paul R, Tsanaclis L, Murray C, Boroujerdi R, Facer L, Corbin A. Ethyl glu-
curonide as a long- term alcohol biomarker in fingernail and hair: matrix 
comparison and evaluation of gender bias. Alcohol. 2019.
 36. Lees R, Kingston R, Williams TM, Henderson G, Lingford-Hughes A, 
Hickman M. Comparison of ethyl glucuronide in hair with self- reported 
alcohol consumption. Alcohol. 2012;47:267–272.
 37. Jousilahti P, Vartiainen E, Alho H, Poikolainen K, Sillanaukee P. 




 http://ahajournals.org by on M
arch 30, 2020
J Am Heart Assoc. 2020;9:e014324. DOI: 10.1161/JAHA.119.014324 11
van de Luitgaarden et al A New Marker for Alcohol in Epidemiologic Research
gamma- glutamyltransferase with prevalent coronary heart disease. 
Arch Intern Med. 2002;162:817–821.
 38. Zatu MC, Van Rooyen JM, Kruger A, Schutte AE. Alcohol intake, hyper-
tension development and mortality in black South Africans. Eur J Prev 
Cardiol. 2016;23:308–315.
 39. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall 
J, Tuomilehto J. Serum gamma- glutamyltransferase predicts non- 
fatal myocardial infarction and fatal coronary heart disease among 
28,838 middle- aged men and women. Eur Heart J. 2006;27: 
2170–2176.
 40. Ndrepepa G, Colleran R, Kastrati A. Gamma- glutamyl transferase and 
the risk of atherosclerosis and coronary heart disease. Clin Chim Acta. 
2018;476:130–138.
 41. Stockwell T, Zhao J, Panwar S, Roemer A, Naimi T, Chikritzhs T. Do, 
“moderate” drinkers have reduced mortality risk? A systematic review 
and meta- analysis of alcohol consumption and all- cause mortality. J 
Stud Alcohol Drugs. 2016;77:185–198.
 42. Xi B, Veeranki SP, Zhao M, Ma C, Yan Y, Mi J. Relationship of alcohol 
consumption to all- cause, cardiovascular, and cancer- related mortality 






















Table S1. Baseline characteristics of 5,676 PREVEND participants, by self-reported alcohol consumption category.  
 Alcohol consumption category (by self-report) 
 
 No, almost never 1-4 units/month 2-7 units/week 1-3 units/day ≥ 4 units/day  
Total N of participants  1366 (24.1%) 960 (16.9%) 1830 (32.2%) 1269 (22.4%) 251 (4.4%) 
Sex:       
Male 497 (36.4%) 420 (43.8%) 1011 (55.2%) 779 (61.4%) 199 (79.3%) 
      
Age (years)  54.8 ± 12.5 53.0 ± 12.6 50.9 ± 11.4 53.5 ± 10.8 54.2 ± 9.8 
BMI (kg/m2) 26.7 [24.1; 30.0] 26.3 [23.7; 29.3] 25.8 [23.4; 28.5] 25.6 [23.5; 28.4] 26.3 [23.5; 29.0] 
 
Smoking:  
     
Never smokers 500 (36.6%) 355 (37.0%) 558 (30.5%) 234 (18.4%) 29 (11.6%) 
 
Educational level: 
     
Low 819 (60.0%) 421 (43.9%) 622 (34.0%) 428 (33.7%) 106 (42.2%) 
 
Physical activity:  
     
No exercise 287 (21.0%) 139 (14.5%) 226 (12.3%) 144 (11.3%) 62 (24.7%) 
 
Comorbidities: 
     
Diabetes 123 (9.0%) 48 (5.0%) 76 (4.2%) 62 (4.9%) 13 (5.2%) 
Hypertension  505 (37.0%) 291 (30.3%) 467 (25.5%) 394 (31.0%) 96 (38.2%) 
Hypercholesterolemia 484 (35.4%) 327 (34.1%) 578 (31.6%) 481 (37.9%) 127 (50.6%) 
Family history CVD  503 (36.8%) 370 (38.5%) 594 (32.5%) 428 (33.7%) 90 (35.9%)  
 
Measurements at baseline 
     
CDT (% of total transferrin) 1.4 [1.2; 1.6] 1.4 [1.2; 1.6] 1.5 [1.3; 1.8] 1.6 [1.4; 1.9] 1.9 [1.6; 2.4] 
HDL-C (mg/dL) 46.5 ± 11.5 47.3 ± 11.4 48.4 ± 12.1 50.5 ± 12.9 50.6 ± 14.3 
eGFR (mL/min/1.73m2) 90.1 ± 17.5 92.3 ± 16.1 95.2 ± 15.3 94.3 ± 15.2 94.4 ± 14.9 








EtG = ethyl glucuronide, BMI = body mass index, CVD = cardiovascular disease, CDT = carbohydrate-deficient transferrin, HDL-C = high density cholesterol, eGFR = estimated 
glomerular filtration rate and PREVEND = Prevention of Renal and Vascular End-Stage Disease. 
 










Table S2. Sensitivity analyses for the associations of EtG with CVD events and all-cause mortality. 
 EtG categories 
 
 
 Undetectable EtG 
(< 100 ng/mL) 
Quintiles of detectable EtG 
(≥ 100 ng/mL) 








Q6 P for trend 
CVD events        
Model 3 1.16 (0.82 – 1.65) Ref  0.60 (0.35 – 1.02) 0.81 (0.50 – 1.32) 1.03 (0.66 – 1.60) 1.06 (0.69 – 1.63) 
 
0.92 
Exclusion of unstable 
consumption (n = 
5464) 
1.19 (0.83 – 1.71) Ref  0.65 (0.38 – 1.11) 0.85 (0.52 – 1.40) 1.09 (0.69 – 1.72) 1.07 (0.68 – 1.67) 0.98 
All-cause mortality        
Model 3 0.89 (0.70 – 1.14) Ref  0.75 (0.53 – 1.06) 1.01 (0.73 – 1.41) 0.94 (0.69 – 1.29) 0.93 (0.67 – 1.27) 0.78 
 
Exclusion of unstable 
consumption (n = 
5464) 
0.92 (0.72 – 1.19) Ref  0.73 (0.51 – 1.04) 1.05 (0.75 – 1.47) 0.95 (0.69 – 1.32) 0.96 (0.69 – 1.32) 0.73 
HRs and 95% confidence intervals for ethyl glucuronide versus the reference category with CVD events and all-cause mortality. 
Models are adjusted for age (years), sex, smoking, education, physical activity, BMI (categories) and parental history of CVD, hypertension, hypercholesterolemia, 
diabetes and renal function (eGFR).  
EtG = ethyl glucuronide, BMI = body mass index, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, HR = hazard ratio, PREVEND = 









Table S3. Associations of time varying self-reported alcohol consumption with all-cause and cause-specific mortality in 5,676 PEVEND participants.  




N = 960 
2-7/week 
N = 1830 
1-3/day 
N = 1269 
≥ 4/day 
N = 251 
P for trend 
All-cause mortality N = 204 (15%) N = 118 (12%) N= 198 (11%) N = 165 (13%) N = 39 (16%)  
Model 3 
 
0.86 (0.69 – 1.07) Ref 0.86 (0.68 – 1.07) 0.77 (0.61 – 0.98)* 0.80 (0.54 – 1.20)  0.06 
CVD mortality N = 43 (3%) N = 28 (3%) N= 48 (3%) N = 25 (3%) N = 5 (2%)  
Model 3 
 
0.71 (0.46 – 1.11) Ref 0.66 (0.41 – 1.07) 0.63 (0.38 – 1.04) 0.54 (0.20 – 1.41)  0.06 
Cancer mortality N = 89 (7%) N = 54 (6%) N = 98 (5%) N = 91 (7%) N = 22 (9%)  
Model 3 
 
0.98 (0.70 – 1.39) Ref 1.24 (0.89 – 1.74) 1.00 (0.70 – 1.43)  1.02 (0.58 – 1.80) 0.75 
Mortality from 
other causes 
N = 72 (5%) N = 36 (4%) N = 52 (3%) N = 42 (3%) N = 12 (5%)  
Model 3 
 
0.82 (0.57 – 1.20) Ref 0.56 (0.36 – 0.85)* 0.62 (0.40 – 0.96)* 0.77 (0.38 – 1.57) 0.03 
HRs and 95% confidence intervals for ethyl glucuronide versus the reference category with CVD events and all-cause mortality. 
Models are adjusted for age (years), sex, smoking, education, physical activity, BMI (categories) and parental history of CVD, hypertension, hypercholesterolemia, 
diabetes and renal function (eGFR).  
EtG = ethyl glucuronide, BMI = body mass index, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, HR = hazard ratio, PREVEND = 
Prevention of Renal and Vascular End-Stage Disease. 
Alcohol consumption categories are displayed in standard units per time period, one standard unit contains 10 grams of alcohol. 
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